Alumis Inc. (ALMS)
| Market Cap | 1.05B +141.9% |
| Revenue (ttm) | 7.40M -63.1% |
| Net Income | -438.96M |
| EPS | -3.80 |
| Shares Out | 129.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,524,710 |
| Open | 8.01 |
| Previous Close | 7.90 |
| Day's Range | 7.67 - 8.14 |
| 52-Week Range | 3.76 - 31.35 |
| Beta | -0.79 |
| Analysts | Strong Buy |
| Price Target | 32.13 (+296.18%) |
| Earnings Date | Aug 13, 2026 |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ALMS stock is "Strong Buy." The 12-month stock price target is $32.13, which is an increase of 296.18% from the latest price.
News
Alumis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Envu demonstrated strong efficacy and safety in psoriasis and promising results in biomarker-positive lupus patients, with NDA filing on track for Q4 and a focus on label differentiation. Pipeline advances include a shift to Parkinson's for A5 and ongoing expansion into new indications, supported by a solid cash runway.
Alumis Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Envudeucitinib demonstrated leading efficacy and safety in plaque psoriasis, with NDA filing planned for Q4. Lupus trial results highlighted the importance of targeting IFN-positive patients, guiding future study design and capital allocation. Partnership discussions are underway to expand the TYK2 franchise.
Alumis Transcript: Wells Fargo 21st Annual Healthcare Conference
Envudeucitinib's phase II lupus trial failed overall due to a high proportion of interferon signature negative patients, but showed strong efficacy in signature positive subgroups. Plans are underway for a phase III trial focused on these patients, while psoriasis development advances toward NDA submission and new indications and pipeline assets are being explored.
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immun...
Alumis downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Alumis (ALMS) to Neutral from Buy without a price target after the Phase IIb study evaluating envudeucitinib in systemic lupus erythematosus missed both primary and secondary end...
Alumis price target lowered to $37 from $55 at Oppenheimer
Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $37 from $55 and keeps an Outperform rating on the shares. Alumis’s 58% intraday decline following the disappointing Phase 2b…
Alumis price target lowered to $25 from $51 at Wells Fargo
Wells Fargo lowered the firm’s price target on Alumis (ALMS) to $25 from $51 and keeps an Overweight rating on the shares. The firm says the stock move seems overdone,…
Alumis price target lowered to $29 from $39 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Alumis (ALMS) to $29 from $39 and keeps an Overweight rating on the shares. The firm is removing envudeucitinib’s SLE indication from…
Alumis upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Alumis (ALMS) to Buy from Neutral with a price target of $15, down from $25. The firm believes the LUMUS study miss removes systemic lupus erythematosus from…
Alumis price target lowered to $27 from $35 at Baird
Baird lowered the firm’s price target on Alumis (ALMS) to $27 from $35 and keeps an Outperform rating on the shares.
Alumis price target lowered to $25 from $51 at Wells Fargo
Wells Fargo lowered the firm’s price target on Alumis (ALMS) to $25 from $51 and keeps an Overweight rating on the shares after the company’s Phase 2b trial of envudeucitinib…
A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It
Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage trial.
Alumis eyes late-stage lupus study despite trial miss
Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a ...
Alumis Transcript: Study result
Envudeucitinib did not meet primary or secondary endpoints in the overall SLE population, but showed robust efficacy and a favorable safety profile in the IFNGS-high subgroup. Future development will focus on this biomarker-defined group, with regulatory engagement planned by year-end.
Alumis Press release: Study result
Alumis issued a press release on September 1, 2026, disclosing material business information to investors.
Alumis Slides: Study result
Alumis has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Alumis reports LUMUS trial did not meet primary, secondary endpoints
Alumis (ALMS) announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus did not meet its primary and secondary endpoints in the ove...
Alumis trading halted, news pending
07:28 EDT Alumis (ALMS) trading halted, news pending
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-...
Alumis reports Q2 revenue $1.66M, consensus $3.47M
“Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Ph...
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
Alumis Earnings release: Q2 2026
Alumis released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.